Table 1 |
||||||
|
Top-20 drugs with highest betweenness centrality in the drug network projection corresponding to level 2 of the ATC hierarchical classification. The associated therapy classes as well as closeness centrality, node degree and number of targets are also displayed. |
||||||
|
Accession Id |
Generic name |
Therapy classes |
Bi centrality |
Ci centrality |
Degree |
Number of targets |
|
|
||||||
|
APRD00616 |
Scopolamine |
A04, N05, S01 |
0.0841 |
0.469 |
155 |
1 |
|
APRD00215 |
Morphine |
G04, N02, N04, R05, S01 |
0.0549 |
0.479 |
164 |
1 |
|
APRD00362 |
Tretinoin |
D10, L01 |
0.0420 |
0.365 |
80 |
3 |
|
APRD01080 |
Magnesium Sulfate |
A06, A12, B05, D11, V04 |
0.0412 |
0.361 |
24 |
3 |
|
APRD00373 |
Celecoxib |
L01, M01 |
0.0340 |
0.356 |
94 |
1 |
|
APRD00047 |
R-mephobarbital |
N03, N05 |
0.0294 |
0.336 |
81 |
1 |
|
APRD00406 |
Physostigmine |
S01, V03 |
0.0261 |
0.454 |
106 |
1 |
|
APRD00807 |
Atropine |
A03, N04, S01 |
0.0251 |
0.460 |
126 |
5 |
|
APRD00479 |
Lidocaine |
C01, C05, D04, N01, R02, S01, S02 |
0.0229 |
0.470 |
166 |
2 |
|
APRD00450 |
Epinephrine |
A01, B02, C01, R01, R03, S01 |
0.0216 |
0.472 |
158 |
3 |
|
APRD00097 |
Orphenadrine |
M03, N04 |
0.0213 |
0.334 |
38 |
5 |
|
APRD00267 |
Tolbutamide |
A10, V04 |
0.0190 |
0.269 |
27 |
2 |
|
APRD01022 |
Hydroxocobalamin |
B03, V03 |
0.0190 |
0.325 |
16 |
8 |
|
APRD00013 |
Neomycin |
A01, A07, B05, D06, J01, R02, S01, S02, S03 |
0.0189 |
0.488 |
187 |
2 |
|
APRD00056 |
Heparin |
B01, C05, S01 |
0.0188 |
0.454 |
121 |
3 |
|
APRD00174 |
Clonidine |
C02, N02, S01 |
0.0185 |
0.461 |
136 |
1 |
|
APRD00326 |
Vitamin B12 |
A11, B03 |
0.0167 |
0.248 |
12 |
7 |
|
APRD00536 |
Vitamin B3 |
C04, C10 |
0.0167 |
0.269 |
21 |
8 |
|
APRD00650 |
Procaine |
C05, D04, J01, N01, S01 |
0.0164 |
0.478 |
199 |
5 |
|
APRD00862 |
Chloramphenicol |
D06, D10, G01, J01, S01, S02, S03 |
0.0157 |
0.496 |
184 |
1 |
|
|
||||||
|
Nacher and Schwartz BMC Pharmacology 2008 8:5 doi:10.1186/1471-2210-8-5 |
||||||